Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Colchicine  COVID-19 treatment studies for Colchicine  C19 studies: Colchicine  Colchicine   Select treatmentSelect treatmentTreatmentsTreatments
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta
Lactoferrin Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent: 
0 0.5 1 1.5 2+ Mortality -36% Improvement Relative Risk Progression -7% primary Ventilation -30% ICU admission 76% Hospitalization time 4% c19early.org/o Perricone et al. NCT04375202 COLVID-19 Colchicine RCT LATE Favors colchicine Favors control
Treatment with COLchicine in hospitalized patients affected by COVID-19: the COLVID-19 trial
Perricone et al., European Journal of Internal Medicine, doi:10.1016/j.ejim.2022.10.016, COLVID-19, NCT04375202 (history)
31 Oct 2022    Source   PDF   Share   Tweet
RCT 152 hospitalized patients in Italy, showing no significant difference in outcomes with colchicine treatment. Table 2 shows 13% of patients treated with antivirals in the colchicine arm, however 16.9% were treated with one specific antiviral (HCQ).
risk of death, 36.4% higher, RR 1.36, p = 0.77, treatment 7 of 77 (9.1%), control 5 of 75 (6.7%).
risk of progression, 7.1% higher, RR 1.07, p = 1.00, treatment 11 of 77 (14.3%), control 10 of 75 (13.3%), mechanical ventilation, ICU, or death, primary outcome.
risk of mechanical ventilation, 29.9% higher, RR 1.30, p = 1.00, treatment 4 of 77 (5.2%), control 3 of 75 (4.0%).
risk of ICU admission, 75.6% lower, RR 0.24, p = 0.21, treatment 1 of 77 (1.3%), control 4 of 75 (5.3%), NNT 25.
hospitalization time, 4.1% lower, relative time 0.96, p = 0.69, treatment mean 14.1 (±10.4) n=77, control mean 14.7 (±8.1) n=75.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Perricone et al., 31 Oct 2022, Randomized Controlled Trial, Italy, peer-reviewed, mean age 69.1, 40 authors, study period 18 April, 2020 - 12 May, 2021, dosage 1.5mg daily, 2mg daily for >100kg, trial NCT04375202 (history) (COLVID-19).
Contact: roberto.gerli@unipg.it.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperColchicineAll
Late treatment
is less effective
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit